RxDoctor Payments Data

Talwinderdeep Kahlon, MD

Cardiovascular Disease · Modesto, CANPI 1366760027

Payments from drug & device makers

$6,592in general payments, 2019–2025

Across 142 payments — averaging $46.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Edwards Lifesciences$2K
  • Boston Scientific$789
  • Medtronic$465
  • Johnson & Johnson$310
  • Novartis$140
  • plus $762 from 15 others

What the payments were for

  • Travel & lodging$2,38136%
  • Food & beverage$4,21164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,592 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$343,967
Medicare patients
919
Services billed
3,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$239,849
Repatha SureclickEvolocumab69$51,950
XareltoRivaroxaban52$45,512
BrilintaTicagrelor33$30,035
Praluent PenAlirocumab26$12,280
Ranolazine ErRanolazine39$4,415
Amiodarone Hcl58$2,346
Metoprolol Succinate157$2,305
Potassium Chloride84$1,853
Atorvastatin Calcium202$1,678
ClopidogrelClopidogrel Bisulfate117$1,631
Rosuvastatin Calcium40$1,243
Nifedipine ErNifedipine18$932
Carvedilol138$875
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$239,849275 claims
Johnson & JohnsonXarelto$310$45,51252 claims
AstraZenecaBrilinta$70$30,03533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →